Objective: To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period.Design, setting and patients: Forty over-weight patients in the Diabetic Clinic, Fremantle Hospital, were studied in a double-blind, placebo-controlled trial with a run-in period of one month followed by three months on either dexfenfluramine or placebo.Main outcome measures: Changes in body weight, and fasting plasma glucose, glycosylated haemoglobin, plasma cholesterol and triglyceride levels.Main Results: The median change in weight was - 3.8 kg in the treatment group (Df) and + 0.3 kg in the placebo group (PI) (P = 0.006). The median changes in fasting plasma glucose levels were - 1.0 mmol/L (Df) and + 0.6 mmol/L (PI) P=0.010). The median changes in glycosylated haemoglobin levels were - 1.4% (Df) and + 0.2% (PI) (P = 0.002). The median changes in triglyceride levels were - 0.3 mmol/L (Df) and + 0.2 mmol/L (PI) (P = 0.017). Cholesterol level did not change significantly.Conclusion: Dexfenfluramine is effective in achieving weight loss and also improved diabetic control in obese type II diabetics over a three-month period.
|Journal||Medical Journal of Australia|
|Publication status||Published - 1993|